FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885873542> ?p ?o ?g. }

• W2885873542 endingPage "176" @default.
• W2885873542 startingPage "167" @default.
• W2885873542 abstract "The clinical management of malignant melanoma remains a challenge because these tumors are intrinsically aggressive and prone to therapeutic resistance. MicroRNA (miR)-211 is an emerging melanoma oncogene. Melanoma metabolism adapts to promote survival, including in response to BRAFV600E inhibition, but how miR-211 participates in this process is unknown. Here, we generated miR-211 loss-of-function cell lines using CRISPR/Cas9 technology and show that miR-211 loss slowed growth and invasion in vitro, inhibited phosphoinositol-3-kinase signaling, and inhibited melanoma growth in vivo. miR-211 deficiency rendered melanoma cells metabolically vulnerable by attenuating mitochondrial respiration and tricarboxylic acid cycling. miR-211 was up-regulated by the BRAF inhibitor vemurafenib and in vemurafenib-resistant melanoma cells, with miR-211 loss rendering them more drug sensitive. miR-211 loss represents a “two-pronged” anticancer strategy by inhibiting both critical growth-promoting cell signaling pathways and rendering cells metabolically vulnerable, making it an extremely attractive and specific candidate combinatorial therapeutic target in melanoma. The clinical management of malignant melanoma remains a challenge because these tumors are intrinsically aggressive and prone to therapeutic resistance. MicroRNA (miR)-211 is an emerging melanoma oncogene. Melanoma metabolism adapts to promote survival, including in response to BRAFV600E inhibition, but how miR-211 participates in this process is unknown. Here, we generated miR-211 loss-of-function cell lines using CRISPR/Cas9 technology and show that miR-211 loss slowed growth and invasion in vitro, inhibited phosphoinositol-3-kinase signaling, and inhibited melanoma growth in vivo. miR-211 deficiency rendered melanoma cells metabolically vulnerable by attenuating mitochondrial respiration and tricarboxylic acid cycling. miR-211 was up-regulated by the BRAF inhibitor vemurafenib and in vemurafenib-resistant melanoma cells, with miR-211 loss rendering them more drug sensitive. miR-211 loss represents a “two-pronged” anticancer strategy by inhibiting both critical growth-promoting cell signaling pathways and rendering cells metabolically vulnerable, making it an extremely attractive and specific candidate combinatorial therapeutic target in melanoma." @default.
• W2885873542 created "2018-08-22" @default.
• W2885873542 creator A5012889147 @default.
• W2885873542 creator A5055624483 @default.
• W2885873542 creator A5056769099 @default.
• W2885873542 creator A5059749084 @default.
• W2885873542 creator A5060115650 @default.
• W2885873542 date "2019-01-01" @default.
• W2885873542 modified "2023-10-15" @default.
• W2885873542 title "MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma" @default.
• W2885873542 cites W1163924930 @default.
• W2885873542 cites W128422138 @default.
• W2885873542 cites W144423133 @default.
• W2885873542 cites W1797193145 @default.
• W2885873542 cites W1966133006 @default.
• W2885873542 cites W1974254202 @default.
• W2885873542 cites W1977709885 @default.
• W2885873542 cites W2028897202 @default.
• W2885873542 cites W2032211985 @default.
• W2885873542 cites W2033708806 @default.
• W2885873542 cites W2041263192 @default.
• W2885873542 cites W2046354919 @default.
• W2885873542 cites W2062289724 @default.
• W2885873542 cites W2066179587 @default.
• W2885873542 cites W2072984024 @default.
• W2885873542 cites W2080534618 @default.
• W2885873542 cites W2080626878 @default.
• W2885873542 cites W2080833200 @default.
• W2885873542 cites W2090387552 @default.
• W2885873542 cites W2097989884 @default.
• W2885873542 cites W2106543129 @default.
• W2885873542 cites W2107513374 @default.
• W2885873542 cites W2113271533 @default.
• W2885873542 cites W2117692326 @default.
• W2885873542 cites W2128096701 @default.
• W2885873542 cites W2128542677 @default.
• W2885873542 cites W2133465414 @default.
• W2885873542 cites W2134294998 @default.
• W2885873542 cites W2140008764 @default.
• W2885873542 cites W2140937677 @default.
• W2885873542 cites W2165759865 @default.
• W2885873542 cites W2168143310 @default.
• W2885873542 cites W2283432584 @default.
• W2885873542 cites W2323141107 @default.
• W2885873542 cites W2336047780 @default.
• W2885873542 cites W2342564029 @default.
• W2885873542 cites W2343222237 @default.
• W2885873542 cites W2412960951 @default.
• W2885873542 cites W2480725775 @default.
• W2885873542 cites W2510540705 @default.
• W2885873542 cites W2528493125 @default.
• W2885873542 cites W2592626516 @default.
• W2885873542 cites W2611567237 @default.
• W2885873542 cites W2612785154 @default.
• W2885873542 cites W2622185466 @default.
• W2885873542 cites W2766466820 @default.
• W2885873542 cites W2771436561 @default.
• W2885873542 doi "https://doi.org/10.1016/j.jid.2018.06.189" @default.
• W2885873542 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6309654" @default.
• W2885873542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30076926" @default.
• W2885873542 hasPublicationYear "2019" @default.
• W2885873542 type Work @default.
• W2885873542 sameAs 2885873542 @default.
• W2885873542 citedByCount "20" @default.
• W2885873542 countsByYear W28858735422018 @default.
• W2885873542 countsByYear W28858735422019 @default.
• W2885873542 countsByYear W28858735422020 @default.
• W2885873542 countsByYear W28858735422021 @default.
• W2885873542 countsByYear W28858735422022 @default.
• W2885873542 countsByYear W28858735422023 @default.
• W2885873542 crossrefType "journal-article" @default.
• W2885873542 hasAuthorship W2885873542A5012889147 @default.
• W2885873542 hasAuthorship W2885873542A5055624483 @default.
• W2885873542 hasAuthorship W2885873542A5056769099 @default.
• W2885873542 hasAuthorship W2885873542A5059749084 @default.
• W2885873542 hasAuthorship W2885873542A5060115650 @default.
• W2885873542 hasBestOaLocation W28858735421 @default.
• W2885873542 hasConcept C104317684 @default.
• W2885873542 hasConcept C145059251 @default.
• W2885873542 hasConcept C2776131300 @default.
• W2885873542 hasConcept C2777609662 @default.
• W2885873542 hasConcept C2777658100 @default.
• W2885873542 hasConcept C2994587330 @default.
• W2885873542 hasConcept C502942594 @default.
• W2885873542 hasConcept C54355233 @default.
• W2885873542 hasConcept C62112901 @default.
• W2885873542 hasConcept C62478195 @default.
• W2885873542 hasConcept C86554907 @default.
• W2885873542 hasConcept C86803240 @default.
• W2885873542 hasConcept C95444343 @default.
• W2885873542 hasConceptScore W2885873542C104317684 @default.
• W2885873542 hasConceptScore W2885873542C145059251 @default.
• W2885873542 hasConceptScore W2885873542C2776131300 @default.
• W2885873542 hasConceptScore W2885873542C2777609662 @default.
• W2885873542 hasConceptScore W2885873542C2777658100 @default.
• W2885873542 hasConceptScore W2885873542C2994587330 @default.
• W2885873542 hasConceptScore W2885873542C502942594 @default.
• W2885873542 hasConceptScore W2885873542C54355233 @default.

• next